BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38347265)

  • 1. Kidney scoring surveillance: predictive machine learning models for clear cell renal cell carcinoma growth using MRI.
    Yazdian Anari P; Zahergivar A; Gopal N; Chaurasia A; Lay N; Ball MW; Turkbey B; Turkbey E; Jones EC; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2024 Apr; 49(4):1202-1209. PubMed ID: 38347265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An MRI-based radiomics model to predict clear cell renal cell carcinoma growth rate classes in patients with von Hippel-Lindau syndrome.
    Anari PY; Lay N; Gopal N; Chaurasia A; Samimi S; Harmon S; Firouzabadi FD; Merino MJ; Wakim P; Turkbey E; Jones EC; Ball MW; Turkbey B; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2022 Oct; 47(10):3554-3562. PubMed ID: 35869307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kidney imaging surveillance scoring system (KISSS): using qualitative MRI features to predict growth rate of renal tumors in patients with von-Hippel Lindau (VHL) syndrome.
    Gopal N; Anari PY; Chaurasia A; Antony M; Wakim P; Linehan WM; Ball M; Turkbey E; Malayeri A
    Abdom Radiol (NY); 2024 Feb; 49(2):542-550. PubMed ID: 38010527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Invasive Tumor Grade Evaluation in Von Hippel-Lindau-Associated Clear Cell Renal Cell Carcinoma: A Magnetic Resonance Imaging-Based Study.
    Zahergivar A; Yazdian Anari P; Mendhiratta N; Lay N; Singh S; Dehghani Firouzabadi F; Chaurasia A; Golagha M; Homayounieh F; Gautam R; Harmon S; Turkbey E; Merino M; Jones EC; Ball MW; Turkbey B; Linehan WM; Malayeri AA
    J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38299714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history and growth kinetics of clear cell renal cell carcinoma in sporadic and von Hippel-Lindau disease.
    Li Z; Zhang J; Zhang L; Yao L; Zhang C; He Z; Li X; Zhou L
    Transl Androl Urol; 2021 Mar; 10(3):1064-1070. PubMed ID: 33850741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep learning-based decision forest for hereditary clear cell renal cell carcinoma segmentation on MRI.
    Lay N; Anari PY; Chaurasia A; Firouzabadi FD; Harmon S; Turkbey E; Gautam R; Samimi S; Merino MJ; Ball MW; Linehan WM; Turkbey B; Malayeri AA
    Med Phys; 2023 Aug; 50(8):5020-5029. PubMed ID: 36855860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease.
    Farhadi F; Nikpanah M; Paschall AK; Shafiei A; Tadayoni A; Ball MW; Linehan WM; Jones EC; Malayeri AA
    Radiology; 2020 Jun; 295(3):583-590. PubMed ID: 32255415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.
    Wang J; Zhang L; Qiu J; Li Z; Wu Y; Zhang C; Yao L; Gong K; Li X; Zhou L
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2631-2641. PubMed ID: 34709473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.
    Coy H; Hsieh K; Wu W; Nagarajan MB; Young JR; Douek ML; Brown MS; Scalzo F; Raman SS
    Abdom Radiol (NY); 2019 Jun; 44(6):2009-2020. PubMed ID: 30778739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma.
    Schuhmacher P; Kim E; Hahn F; Sekula P; Jilg CA; Leiber C; Neumann HP; Schultze-Seemann W; Walz G; Zschiedrich S
    Orphanet J Rare Dis; 2019 Oct; 14(1):235. PubMed ID: 31661010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease.
    Serghini A; Portelli S; Troadec G; Song C; Pan Q; Pires DEV; Ascher DB
    Hum Mol Genet; 2024 Jan; 33(3):224-232. PubMed ID: 37883464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
    Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
    Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinctive clinicopathological features of Von Hippel-Lindau-associated hereditary renal cell carcinoma: A single-institution study.
    Hong B; Zhang Z; Zhou J; Ma K; Zhang J; Cai L; Zhang N; Gong K
    Oncol Lett; 2019 May; 17(5):4600-4606. PubMed ID: 30944649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Single Nucleotide Polymorphisms in the Von Hippel-Lindau Tumor Suppressor Gene in Patients with Clear Cell Renal Cell Carcinoma.
    Chrabańska M; Szweda-Gandor N; Drozdzowska B
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.